Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report Download FREE Resources

Published: October 14, 2026 Report Code: GDHC348PIDR-7M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the obesity market through 2035.

– In 2025, GlobalData estimated the total obesity market to be valued at $34.6 billion across the 7MM, with the US accounting for 82.6% of the market. Over the forecast period, the obesity market is anticipated to grow to a value of $118.2 billion in 2035.
– There will be an increase in therapies with longer duration of action, such as Novo’s CagriSema (semaglutide + cagrilintide) and zenagamtide, Eli Lilly’s tirzepatide and retatrutide, and Amgen’s MariTide, consequently improving patient compliance for obesity patients who may already experience a heavy treatment burden due to comorbid conditions.
– Multi-organ label expansion is broadening the clinical and reimbursement rationale, with glucagon-like peptide 1 (GLP-1) agents moving beyond weight loss and type 2 diabetes (T2D) and into cardiovascular risk reduction, metabolic dysfunction-associated steatohepatitis (MASH), and chronic kidney disease (CKD), among other indications.
– Therapies with new routes of administration will enter the market, such as Novo’s Wegovy pill (oral semaglutide), Eli Lilly’s Foundayo (orforglipron), Structure Therapeutics’ GSBR-1290, and other oral agents with different mechanisms of actions, such as enobosarm.

Scope

Overview of obesity, including epidemiology, symptoms, diagnosis, and disease management.

Annualized obesity therapeutics market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy and treatment usage pattern in 2025 and forecast for 10 years to 2035.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the obesity therapeutics market.

Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for obesity treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the 7MM obesity therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the obesity therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the obesity therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Alveus Therapeutics
Amgen
Ascletis Pharma
AstraZeneca
BioAge Labs
Biomed Industries
Boehringer Ingelheim
Carmot Therapeutics
CHEPLAPHARM
Currax Pharmaceuticals
Ecogene
Eli Lilly
H2-Pharma
Hansoh
Jiangsu Hengrui Pharmaceuticals
Kailera Therapeutics
Mitsubishi Tanabe
Novo Nordisk
Orexigen Therapeutics
Pfizer
Regeneron
Rhythm Pharmaceuticals
Roche
Sciwind Biosciences
Structure Therapeutics
Veru
Viking Therapeutics
Vivus
Zealand Pharma

List of Contents

List of Tables

List of Figures

1 Executive Summary

1.1 Market overview

1.2 The obesity market will grow significantly during the forecast period, reaching sales of $118.2 billion in 2035

1.3 Key players will maintain their competitive position

1.4 While the outlook in obesity improves, opportunities remain to improve patient outcomes

1.5 Late-stage pipeline therapies are anticipated to drive growth in the obesity market

1.6 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Global and historical trends

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: total prevalent cases of overweight and obesity

4.4.4 Diagnosed prevalent cases of overweight and obesity

4.4.5 Total and diagnosed prevalent cases of overweight and obesity by BMI class

4.4.6 Total and diagnosed prevalent cases of pediatric obesity by severity

4.4.7 Diagnosed prevalent cases of obesity by comorbidity

4.5 Epidemiological forecast for overweight and obesity (2025–35)

4.5.1 Total prevalent cases of overweight

4.5.2 Total prevalent cases of obesity

4.5.3 Diagnosed prevalent cases of overweight

4.5.4 Age-specific diagnosed prevalent cases of overweight

4.5.5 Sex-specific diagnosed prevalent cases of overweight

4.5.6 Diagnosed prevalent cases of overweight by BMI class

4.5.7 Diagnosed prevalent cases of obesity

4.5.8 Age-specific diagnosed prevalent cases of obesity

4.5.9 Sex-specific diagnosed prevalent cases of obesity

4.5.10 Diagnosed prevalent cases of pediatric obesity by severity

4.5.11 Diagnosed prevalent cases of adult obesity by BMI class

4.5.12 Diagnosed prevalent cases of obesity by comorbidity

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.1.1 Treatment overview

5.2 Key opinion leader insights on disease management

5.2.1 Treatment approach

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Long-term weight maintenance

7.3 GI tolerability/side-effect burden

7.4 Lean mass preservation and metabolic adaptation

7.5 Cost of therapy

7.6 Specialist capacity and structural prescribing access

8 R&D Strategies

8.1 Overview

8.1.1 Multi-receptor agonism

8.1.2 Development of oral agents

8.2 Clinical trials design

8.2.1 Clinical endpoints for obesity

8.2.2 Inclusion and exclusion criteria for obesity

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Seven major markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecast methodology

13.4 Primary research- KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologists

13.6.4 Reviewers

13.6.5 Vice President of Disease Intelligence and Epidemiologists

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: Obesity: Key metrics in the 7MM

Table 2: Classifications of obesity as outlined by the WHO

Table 3: Classification systems for obesity based on BMI cutoff points

Table 4: Risk factors and comorbidities for overweight and obesity

Table 5: Treatment guidelines for obesity

Table 6: Top 10 deals by value, 2021-26

Table 7: Obesity market – drivers and barriers in the 7MM, 2025–35

Table 8: Key events impacting sales for obesity in the US, 2025–35

Table 9: Obesity market – drivers and barriers in the US, 2025–35

Table 10: Key events impacting sales for obesity in the 5EU, 2025–35

Table 11: Obesity market – drivers and barriers in the 5EU, 2025–35

Table 12: Key events impacting sales for obesity in Japan, 2025–35

Table 13: Obesity market – drivers and barriers in Japan, 2025–35

Table 14: High-prescribing physicians surveyed, by country

Figures

Figure 1: Global sales forecast by country for obesity in 2025 and 2035

Figure 2: Analysis of the company portfolio gap in obesity during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period

Figure 4: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period

Figure 5: Factors involved in the etiology of obesity

Figure 6: Pathophysiological manifestation of obesity

Figure 7: 7MM, total prevalence of overweight, men and women, %, ≥5 years, 2015–35

Figure 8: 7MM, total prevalence of obesity, men and women, %, ≥5 years, 2015–35

Figure 9: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight

Figure 10: 7MM, sources used to forecast the total and diagnosed prevalent cases of obesity

Figure 11: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight by BMI class

Figure 12: 7MM, sources used to forecast the total and diagnosed prevalent cases of obesity by BMI class

Figure 13: 7MM, sources used to forecast the total and diagnosed prevalent cases of pediatric obesity by severity

Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of obesity by comorbidity

Figure 15: 7MM, total prevalent cases of overweight, N, both sexes, age ≥5 years, 2025

Figure 16: 7MM, total prevalent cases of obesity, N, both sexes, age ≥5 years, 2025

Figure 17: 7MM, diagnosed prevalent cases of overweight, N, both sexes, age ≥5 years, 2025

Figure 18: 7MM, diagnosed prevalent cases of overweight by age, N, both sexes, age ≥5 years, 2025

Figure 19: 7MM, diagnosed prevalent cases of overweight by sex, N, both sexes, age ≥5 years, 2025

Figure 20: 7MM, diagnosed prevalent cases of overweight by BMI class, N, both sexes, age ≥5 years, 2025

Figure 21: 7MM, diagnosed prevalent cases of obesity, N, both sexes, age ≥5 years, 2025

Figure 22: 7MM, diagnosed prevalent cases of obesity by age, N, both sexes, age ≥5 years, 2025

Figure 23: 7MM, diagnosed prevalent cases of obesity by sex, N, both sexes, age ≥5 years, 2025

Figure 24: 7MM, diagnosed prevalent cases of pediatric obesity by severity, N, both sexes, ages 5─17, 2025

Figure 25: 7MM, diagnosed prevalent cases of obesity by BMI class, N, both sexes, age ≥18 years, 2025

Figure 26: 7MM, diagnosed prevalent cases of obesity by comorbidity, N, both sexes, age ≥18 years, 2025

Figure 27: BMI chart as a diagnostic technique for obesity

Figure 28: Treatment algorithm for obesity

Figure 29: Unmet needs and opportunities in obesity

Figure 30: Overview of the development pipeline in obesity

Figure 31: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for the treatment of obesity in the 7MM during the forecast period

Figure 32: Competitive assessment of the recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period

Figure 33: Competitive assessment of the pipeline drugs benchmarked against standard of care

Figure 34: Analysis of the company portfolio gap in obesity during the forecast period

Figure 35: 7MM sales forecast by country for obesity in 2025 and 2035

Figure 36: 7MM sales forecast by drug for obesity in 2025 and 2035

Figure 37: Sales forecast by drug class for obesity in the US in 2025 and 2035

Figure 38: Sales forecast by drug for obesity in the 5EU in 2025 and 2035

Figure 39: Sales forecast by drug for obesity in Japan in 2025 and 2035

Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports

Pharmaceuticals

New

Gonorrhea: Market View, Current and Future Competitive Landscape

Pharmaceuticals

New

Ulcerative Colitis (UC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet…

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 in real time.

Access a live Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports